Therefore, the ML-based ultrasomic model serves as an accurate and noninvasive tool for predicting objective response to TKI and anti-PD-1 combination therapy for HCC patients, which is essential for developing management strategies and enhancing patient outcomes. Here, PDCD1 is linked to hepatocellular carcinoma.